{
    "clinical_study": {
        "@rank": "6509", 
        "acronym": "SPAD", 
        "arm_group": [
            {
                "arm_group_label": "GET 73", 
                "arm_group_type": "Active Comparator", 
                "description": "300 mg (3 capsules) tid for 3 days"
            }, 
            {
                "arm_group_label": "inactive ingredients capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 capsules tid for 3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Examination of the effect of GET 73 on alcohol pharmacokinetics and pharmacodynamics\n      (intoxication and sedation)and safety profile in alcohol-dependent individuals.To evaluate\n      whether GET 73, as compared to placebo, results in diminished cue-reactivity responses to\n      alcohol cues in terms of urge to drink during the cue reactivity session and results in\n      lower quantity of alcohol consumed during an alcohol self-administration session."
        }, 
        "brief_title": "Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcohol Dependence", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female subjects, between 21 and 65 years old (inclusive);\n\n          -  participants must meet criteria for current Diagnostic and Statistical Manual\n             (DSM-IV)diagnosis of alcohol dependence,supported by the structured clinical\n             interview for DSM-IV Axis I Disorders Patient Edition;\n\n          -  participants must meet criteria for heavy drinking, defined as averaging\n\n               -  4 drinks/day for women and \u22655 drinks/day for men during a 30-day period within\n                  the 90 days prior to screening evaluation;\n\n          -  participants must be in good health as confirmed by medical history, physical\n             examination, ECG, lab tests;\n\n          -  females must be postmenopausal for at least one year or surgically sterile.\n             Otherwise, females will be excluded (even if they are using any kind of birth\n             control). Proof (medical records, certification from an medical doctor) of surgical\n             sterility will be required. Certification of postmenopausal for at least 1 year and\n             postmenopausal levels of FSH will also be required to be into the study;\n\n          -  participants must be willing to take oral medication and adhere to the study\n             procedures;\n\n          -  participants must give their consent to enter the study by signing the informed\n             consent form.\n\n        Exclusion Criteria:\n\n          -  individuals seeking treatment for alcohol dependence;\n\n          -  positive urine drug screen at baseline for positive drug screen for the following:\n             opioids, benzodiazepines, cocaine, methamphetamine or any other stimulants. A urine\n             drug screen may be repeated once and must test negative before randomization;\n\n          -  individuals diagnosed with a current substance dependence, other than alcohol or\n             nicotine;\n\n          -  meet DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar\n             disorder, or other psychoses;\n\n          -  Subjects taking any psychoactive medication that in the opinion of the subjects\n             primary care physician, cannot be discontinued at least 14 days prior to being\n             randomized;\n\n          -  an active illness within the past 6 months of Visit 1 that meet the DSM-IV criteria\n             for a diagnosis of Major Depressive Disorder or Anxiety Disorder;\n\n          -  subjects with a history of suicide attempts and/or at risk for suicide will be\n             excluded, based on the Structured Clinical Interview Disorders assessment and on the\n             Investigators' evaluation;\n\n          -  clinically significant medical abnormalities (i.e., unstable hypertension, clinically\n             significant abnormal ECG, bilirubin > 150% of the upper normal limit, alanine\n             aminotransferase or  aspartate aminotransferase elevations >300% the upper normal\n             limit, estimated creatinine clearance \u2264 60 dl/min);\n\n          -  current use of any medications prescribed to reduce alcohol use e.g. naltrexone,\n             acamprosate, disulfiram or topiramate;\n\n          -  concomitant use of cytochromeP450 2C19 substrates; assumption of cytochromeP450 2C19\n             and cytochromeP450 3A4 inhibitors or inducers in the 14 days before dosing;\n\n          -  individuals with a reasonable expectation of being institutionalized during the\n             course of the trial;\n\n          -  participants who have significant alcohol withdrawal symptoms, defined as a Clinical\n             Institute Withdrawal Assessment >10;\n\n          -  history of seizures (e.g. epilepsy), including alcohol-related seizures;\n\n          -  history of delirium tremens;\n\n          -  subjects who have participated in any behavioral and/or pharmacological study within\n             the past 30 days;\n\n          -  history of delirium tremens."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842503", 
            "org_study_id": "73CT-2-03", 
            "secondary_id": "2012-005515-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "GET 73", 
                "description": "300 mg tid on 3 days cycle", 
                "intervention_name": "GET 73", 
                "intervention_type": "Drug", 
                "other_name": "GET 73"
            }, 
            {
                "arm_group_label": "inactive ingredients capsule", 
                "description": "3 capsules tid on 3 days cycle", 
                "intervention_name": "inactive ingredients capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "alcohol dependence", 
            "cue reactivity", 
            "alcohol self administration"
        ], 
        "lastchanged_date": "September 27, 2013", 
        "location": {
            "contact": {
                "email": "robert_swift_md@brown.edu", 
                "last_name": "Robert M. Swift, M.D., R.Ph.", 
                "phone": "401-457-3066"
            }, 
            "facility": {
                "address": {
                    "city": "Providence", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02908"
                }, 
                "name": "Roger Williams Medical Center"
            }, 
            "investigator": {
                "last_name": "Robert M. Swift, M.D., R.Ph.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects", 
        "overall_contact": {
            "email": "robert_swift_md@brown.edu", 
            "last_name": "Robert M. Swift, M.D., R.Ph.", 
            "phone": "(401) 457-3066"
        }, 
        "overall_official": {
            "affiliation": "Roger Williams Medical Center", 
            "last_name": "Robert M. Swift, M.D., R.Ph.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "On Day 2 and Day 12 subjects have an indwelling catheter placed in a forearm vein for blood draws. After the 5th dose of GET 73 or placebo is administered on Day 2 and Day 12, participants receive a dose of alcohol 30 minutes later, which is calculated to produce a peak of 0.08 g/L, based on body water content.\nAUC will be evaluated as mean value of overall subjects evaluated", 
                "measure": "changes in area under the plasma concentration of alcohol versus time curve (AUC), after administration of GET 73 or placebo", 
                "safety_issue": "No", 
                "time_frame": "blood samples are drawn on day 2 and day 12 at baseline  and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations"
            }, 
            {
                "measure": "Changes in pleasurable and negative effects of alcohol intoxication and sedation, measured by the Biphasic Alcohol Effects Scales (BAES),during the Alcohol Self-Administration (ASA) session, when taking GET 73 compared to placebo.", 
                "safety_issue": "Yes", 
                "time_frame": "The BAES will be administered, at Day 2 and Day 12, eight times after the priming drink is presented during the ASA."
            }, 
            {
                "measure": "Changes in reaction time, measured by Conners's Continuous Performance Task (CPT),when taking GET 73 compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "CPT will be assessed at Day 2 and Day 12"
            }, 
            {
                "measure": "Changes in cognitive performance, measured by Digit Symbol Substitution Test (DSST), when taking GET 73 compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "DSST will be assessed at Day 2 and Day 12"
            }, 
            {
                "description": "All AEs occurring during the study will be recorded. Subjects are discharged from the hospital at Day 13, after the two inpatient treatment phases (Day 1-Day 3 and Day 11-Day 13). A follow-up visit, approximately from 7 to 14 days after the second CR/ASA experiment, will be performed. The AEs will be grouped by Medical Dictionary for Regulatory Affairs preferred terms into frequency tables according to system organ class (SOC).\nFrequencies of AEs occurred after placebo or GET 73 administration will be compared using chi-square or Fischer's exact test.", 
                "measure": "Frequency of adverse events (AEs) occured after placebo or GET 73 administration", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20-27 days"
            }, 
            {
                "description": "To evaluate whether GET 73, as compared to placebo, results in reductions in craving (as measured by the AUQ), the AUQ will be administered eight times after the priming drink is presented during the ASA.", 
                "measure": "Changes in cue reactivity (CR) responses to alcohol cues, in terms of urge to drink, as measured by the Alcohol Urge Questionnaire (AUQ), when taking GET 73 compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "At Day 3 and Day 13 during the two treatment phases"
            }, 
            {
                "description": "There are three experimental time periods of 3-minutes each during each CR session. Cotton swabs will be weighed at the end of each 3-minute block and the mean values for weight of salivation will be calculated. An average heart rate and an average mean arterial pressure will be calculated for each of these three time periods.", 
                "measure": "Changes in CR responses to alcohol cues, in terms of psychophysiological responses,heart rate,mean arterial pressure and salivation changes during the CR session.", 
                "safety_issue": "No", 
                "time_frame": "At Day 3 and Day 13 during the two treatment phases"
            }, 
            {
                "measure": "Changes in attention to the sight and smell of cues, as measured by Alcohol Attention Scale (AAS), during the CR.", 
                "safety_issue": "No", 
                "time_frame": "This endpoint will be measured twice in each CR session (Day 3 and Day 13) through the AAS."
            }, 
            {
                "measure": "Effects of GET 73 on the amount of alcohol consumed during the ASA. The maximum quantity of alcohol will be taken, to have a measure directly comparable to AUQ results", 
                "safety_issue": "No", 
                "time_frame": "At Day 3 and Day 13 during the two treatment phases"
            }, 
            {
                "description": "Cmax will be calculated at the peak level as mean value of overall subjects evaluated", 
                "measure": "Changes in peak plasma concentration (Cmax) of alcohol after administration of GET 73 or placebo", 
                "safety_issue": "No", 
                "time_frame": "blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations"
            }, 
            {
                "description": "Tmax will be evaluated as the time after administration corresponding to the time of peak plasma level and as mean value of overall subjects evaluated", 
                "measure": "Changes in time to peak plasma level (Tmax) of alcohol after administration of GET 73 or placebo", 
                "safety_issue": "No", 
                "time_frame": "blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations"
            }, 
            {
                "description": "Half-life will be calculated as mean value of overall subjects evaluated", 
                "measure": "Changes in half-life of alcohol after administration of GET 73 or placebo", 
                "safety_issue": "No", 
                "time_frame": "blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations"
            }, 
            {
                "description": "All AEs occurring during the study will be recorded. Subjects are discharged from the hospital at Day 13, after the two inpatient treatment phases (Day 1-Day 3 and Day 11-Day 13). A follow-up visit, approximately from 7 to 14 days after the second CR/ASA experiment, will be performed. The AEs will be grouped by Medical Dictionary for Regulatory Affairs preferred terms according to system organ class (SOC). When an AE occurs more than once for a subject, the maximal severity and strongest relationship to the medication will be counted.\nCharacteristics of AEs occurred after placebo or GET 73 administration will be compared using chi-square or Fischer's exact test.", 
                "measure": "Characteristics of adverse events (AEs) occured after placebo or GET 73 administration", 
                "safety_issue": "Yes", 
                "time_frame": "up to 20-27 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Laboratorio Farmaceutico Ct S.r.l.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Voisin Consulting, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Latis Srl", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Quotient Bioresearch Ltd", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Laboratorio Farmaceutico Ct S.r.l.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}